within Pharmacolibrary.Drugs.ATC.S;

model S01EB51
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.001,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01EB51</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pilocarpine, in combination with other agents, is a miotic and cholinergic agent commonly used as an ophthalmic solution to induce miosis, reduce intraocular pressure in glaucoma, and manage xerostomia related to radiation or Sjögren’s syndrome. Its main contemporary use is in ophthalmology, but combination forms are less common in modern clinical use, although some fixed-dose combinations are approved in certain regions.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data are available for pilocarpine in fixed-dose combination ophthalmic products (ATC S01EB51); values below represent rough estimations based on single-agent topical pilocarpine studies in adults.</p><h4>References</h4><ol><li><p>Doughty, MJ, &amp; Lyle, WM (1992). A review of the clinical pharmacokinetics of pilocarpine, moxisylyte (thymoxamine), and dapiprazole in the reversal of diagnostic pupillary dilation. <i>Optometry and vision science : official publication of the American Academy of Optometry</i> 69(5) 358–368. DOI:<a href=\"https://doi.org/10.1097/00006324-199205000-00005\">10.1097/00006324-199205000-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1350669/\">https://pubmed.ncbi.nlm.nih.gov/1350669</a></p></li><li><p>Kompella, UB, et al., &amp; Patil, MA (2021). Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma. <i>Progress in retinal and eye research</i> 82 100901–None. DOI:<a href=\"https://doi.org/10.1016/j.preteyeres.2020.100901\">10.1016/j.preteyeres.2020.100901</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32891866/\">https://pubmed.ncbi.nlm.nih.gov/32891866</a></p></li><li><p>Tang-Liu, DD, &amp; Richman, JB (1994). The effect of pilocarpine on ocular levobunolol absorption from ophthalmic solutions. <i>Journal of ocular pharmacology</i> 10(4) 605–615. DOI:<a href=\"https://doi.org/10.1089/jop.1994.10.605\">10.1089/jop.1994.10.605</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7714404/\">https://pubmed.ncbi.nlm.nih.gov/7714404</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01EB51;
